Trial Profile

A prospective, open, randomized, multicenter study comparing the effects of everolimus versus mycophenolate sodium as compared to ciclosporin as maintenance therapy in renal allograft recipients, on chronic allograft damage and cardiovascular parameters.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Feb 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Mycophenolate sodium (Primary) ; Prednisolone
Indications Renal transplant rejection
Focus Adverse reactions
Acronyms MECANO

17 Sep 2016 Results published in the American Journal of Transplantation
17 Sep 2016 Primary endpoint has been met. (Degree of inflammation and fibrosis and degree of arteriolar hyalinosis in renal biopsies taken at 6 and 24 months after implantation for prednisolone/Everolimus (P/EVL) arm), according to Results published in the American Journal of Transplantation.
17 Sep 2016 Results published in the American Journal of Transplantation

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com